Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $2.60, $0.18 worse than the analyst estimate of $2.78. Revenue for the quarter came in at $680.8 million versus the consensus estimate of $679.94 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.